Identification of Risk Factors Parkinson's Disease by Convergence Strategy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Parkinson Disease
- Sponsor
- University Hospital, Lille
- Enrollment
- 2220
- Locations
- 1
- Primary Endpoint
- Significant variations in the frequencies of gene polymorphisms and the risk of developing Parkinson's disease
- Status
- Completed
- Last Updated
- 5 months ago
Overview
Brief Summary
Using this convergence approach from a limited group of subjects with non-diseased controls, patients with Parkinson's disease or related diseases, we will be able to limit the number of potential genes of specific susceptibility to Parkinson disease. These genes will then be studied using a case-control genetic epidemiology approach. The risk of developing the disease will then be evaluated according to clinical, biological and environmental variables collected in Parkinson's subjects and healthy controls in the second group of subjects. The specificity of the genetic associations found will be evaluated in subjects with Parkinson's disease.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion criteria for Parkinson's patients and "related diseases" controls:
- •Parkinsonian patients meeting the Gelb criteria
- •Patients with other neurodegenerative disease (such as other Parkinson syndrome or synucleopathies) meeting the criteria set out in Appendix 2 (Lewy Bodies dementia, Parkinson's disease with dementia, MultiSystem atrophy, Progressive Supranuclear Paralysis) , Amyotrophic Lateral Sclerosis, Restless Legs Syndrome, Alzheimer's Disease).
- •Woman of childbearing age having an effective means of contraception.
- •Informed consent signed by the subject or his legal representative.
- •For demented subjects coming for consultation or day hospitalization with an accompanying person, signature of the legal representative.
- •Criteria for inclusion of non-ill controls:
- •Absence of rest trembling, bradykinesia and stiffness
- •MMSE (Mini Mental State Examination) greater than 25
- •Woman of childbearing age having an effective means of contraception.
Exclusion Criteria
- •Criteria for non-inclusion of patients:
- •Clinical criteria for exclusion of the diseases described
- •Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.
- •Criteria for non-inclusion of non-ill controls:
- •Functional discomfort in daily life of unknown cause
- •MMSE less than 25
- •Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.
Outcomes
Primary Outcomes
Significant variations in the frequencies of gene polymorphisms and the risk of developing Parkinson's disease
Time Frame: through study completion, an average of 10 years
the frequency is measured according to biological and environmental variables modulating the risk of developing Parkinson's disease.